Tadalafil-Delivra and Raynaud's Phenomenon

Raynaud Phenomenon Clinical Trial

Official title:

A Multicenter Observational Pilot Study on the Use of Tadalafil Delivra Cream in the Treatment of Raynaud's Phenomenon and Pain Associated With Digital Ulcers

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03393325
• Other study ID #: TAD-Sc-0001
• Status: Withdrawn
• Start date: October 2018
• Est. completion date: September 2019

Study information

• Verified date: September 2018
• Source: Lawson Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A 4-8 week observational feasibility study of the use of the use of Tadalafil-Delivra in the treatment of Reynaud's Phenomena (RP).

Description:

To determine if the feasibility of conducting a future RCT using the chosen outcome assessments in RP patients at 2 Rheumatology clinics.

Study Design:

Observation of patients prescribed Tadalafil-Delivra 2% (Tad-Del) for the treatment of RP with defined feasibility objectives and data collection through efficacy and safety assessments. Study objectives are:

• At least 70% recruitment of eligible participants.

• 100% data collection from at least 70% of all enrolled subjects.

• Estimate the standard deviation(s) of all outcome assessments.

Setting/Participants:

Patients prescribed Tad-Del will be screened for study enrollment at 2 participating rheumatology clinics by the local research team. Participants that meet all the eligibility criteria will be enrolled in the study as subjects. Subjects will self-administer the medication as prescribed and return to the clinic for follow-up. Data will be collected on outcome assessments at: baseline, 1 week and at 4 to 8 weeks of treatment.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2019
• Est. primary completion date: June 2019
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Adults of both genders, Age 18 to 75 years.

2. Patients with a confirmed diagnosis of Raynaud's Phenomenon (RP).

3. Written informed consent.

4. The presence of 1 or more digital ulcers (DU), that is not related to calcinosis, anywhere on a finger that is symptomatic for RP- defined as a VAS pain score of =25mm of 100mm Or 1 -3 fingers that are symptomatic for RP under standard of care treatment (SoC). Symptomatic is defined as a VAS pain score of = 25mm of 100mm.

5. Prescribed, but not currently being treated with Tad-Del.

6. Maintenance of a stable background of prescribed treatment for RP including vasodilators, orally administered PDE5i and pain medication. Changes to administration of this concomitant medication will be documented in the case report form (CRF).

Exclusion Criteria:

1. Unwilling and/or incapable of adhering to the study procedures and follow-up schedule.

2. Use of other prescribed topical treatment for RP, such as nitrates.

3. Active infection of the index ulcer

4. Calcinosis at the site of the index ulcer

5. Received Iloprost or other prostacyclin treatment in the last 4 months.

6. Unsuitable for study participation as determined by the clinical investigator.

Related Conditions & MeSH terms

• Raynaud Disease
• Raynaud Phenomenon

Intervention

Other:
• Observation of treatment with Tadalafil-Delivra
Tadalafil 2% in a Delivra base (Transdermal Application)

Locations

Country	Name	City	State
Canada	St. Joseph's Healthcare	Hamilton	Ontario
Canada	Mount Sinai Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Lawson Health Research Institute	Delivra, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS-100 of DU & RP severity over the previous week assessed by patient & MD	Visual Analogue Scale (VAS) of the severity of Digital Ulcers (DU) and Raynaud's Phenomenon (RP). The physician (MD) and patient will each independently make their own assessment on a linear 10 cm VAS scale by making a mark on the line with a pen anywhere from the left anchor "0" (indicating no disease at all) to the right anchor "10" (indicating the most severe imaginable). Both the MD and patient will complete an individual scale for RP and DU. The distance of the mark from the left anchor "0" will be recorded in mm, divided by 10 and reported as a value from 0 to 10. A total of 4 VAS scales will be completed.	28 days [this assessment has a window of an additional 28 days (Day 56) to be completed]
Secondary	Change in RP and DU interference in daily activities as measured by VAS-100 in SHAQ.	Visual Analogue Scales for Raynaud's Phenomenon and Digital Ulcer interference in daily activities as measured by the patient. Both assessments are part of the Scleroderma Health Assessment Questionnaire (SHAQ). The patient will make an assessment on the linear VAS scale for each by making a mark on the line with a pen anywhere from the left anchor "Does not limit activities" to the right anchor "Very Severe limitation". The distance of the mark from the left to the right anchor will be measured in mm, divided by 10 and reported as a value from 0 to 10. There are two scales: 1 for Raynaud's Phenomena and the other for Digital Ulcer.	28 days [this assessment has a window of an additional 28 days (Day 56) to be completed]
Secondary	changes in the use of concurrent RP therapy and pain medications in patients treated with Tad-Del.	Concomitant medication use at the end of treatment (day 28-56) will be compared with concomitant medication use at baseline with respect to daily dose administered.	28 days [this assessment has a window of an additional 28 days (Day 56) to be completed]
Secondary	All adverse Event experienced by the patient during study participation (1st to last visit) will be recorded.	Adverse events will be summarized and reported at the end of treatment.	28 days [this assessment has a window of an additional 28 days (Day 56) to be completed]